Search

Your search keyword '"Moschovitis, Aris"' showing total 358 results
Start Over Author "Moschovitis, Aris"
358 results on '"Moschovitis, Aris"'

2. Clinical Characteristics and Outcomes of Patients Screened for Transcatheter Tricuspid Valve Replacement: The TriACT Registry

Author

Hagemeyer, Daniel, Merdad, Anas, Sierra, Laura Villegas, Ruberti, Andrea, Kargoli, Faraj, Bouchat, Marine, Boiago, Mauro, Moschovitis, Aris, Deva, Djeven P., Stolz, Lukas, Ong, Geraldine, Peterson, Mark D., Piazza, Nicolo, Taramasso, Maurizio, Dumonteil, Nicolas, Modine, Thomas, Latib, Azeem, Praz, Fabien, Hausleiter, Jörg, and Fam, Neil P.

Published
2024
Full Text
View/download PDF

3. Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)

Author

Chang, Chun Chin, Spitzer, Ernest, Chichareon, Ply, Takahashi, Kuniaki, Modolo, Rodrigo, Kogame, Norihiro, Tomaniak, Mariusz, Komiyama, Hidenori, Yap, Sing-Chien, Hoole, Stephen P., Gori, Tommaso, Zaman, Azfar, Frey, Bernhard, Ferreira, Rui Cruz, Bertrand, Olivier F., Koh, Tian Hai, Sousa, Amanda, Moschovitis, Aris, van Geuns, Robert-Jan, Steg, Philippe Gabriel, Hamm, Christian, Jüni, Peter, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, Serruys, Patrick W., Soliman, Osama, and Onuma, Yoshinobu

Published
2019
Full Text
View/download PDF

5. Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation: Insights From the First-in-Human Experience

Author

Asmarats, Lluis, Perlman, Gidon, Praz, Fabien, Hensey, Mark, Chrissoheris, Michael P., Philippon, Francois, Ofek, Hadass, Ye, Jian, Puri, Rishi, Pibarot, Philippe, Attinger, Adrian, Moss, Robert, Bédard, Elisabeth, Moschovitis, Aris, Reineke, David, Lauck, Sandra, Blanke, Philipp, Leipsic, Jonathon, Spargias, Konstantinos, Windecker, Stephan, Webb, John G., and Rodés-Cabau, Josep

Published
2019
Full Text
View/download PDF

8. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial

Author

Smits, Pieter C., Frigoli, Enrico, Tijssen, Jan, Jüni, Peter, Vranckx, Pascal, Ozaki, Yukio, Morice, Marie-Claude, Chevalier, Bernard, Onuma, Yoshinobu, Windecker, Stephan, Tonino, Pim A.L., Roffi, Marco, Lesiak, Maciej, Mahfoud, Felix, Bartunek, Jozef, Hildick-Smith, David, Colombo, Antonio, Stankovic, Goran, Iñiguez, Andrés, Schultz, Carl, Kornowski, Ran, Ong, Paul J.L., Alasnag, Mirvat, Rodriguez, Alfredo E., Moschovitis, Aris, Laanmets, Peep, Heg, Dik, and Valgimigli, Marco

Published
2021
Full Text
View/download PDF

9. Transcatheter Tricuspid Valve Repair With a New Transcatheter Coaptation System for the Treatment of Severe Tricuspid Regurgitation: 1-Year Clinical and Echocardiographic Results

Author

Perlman, Gidon, Praz, Fabien, Puri, Rishi, Ofek, Hadass, Ye, Jian, Philippon, Francois, Carrel, Thierry, Pibarot, Philippe, Attinger, Adrian, Htun, Nay Min, Dvir, Danny, Moss, Robert, Campelo-Parada, Francisco, Bédard, Elisabeth, Reineke, David, Moschovitis, Aris, Lauck, Sandra, Blanke, Philipp, Leipsic, Jonathon, Windecker, Stephan, Rodés-Cabau, Josep, and Webb, John

Published
2017
Full Text
View/download PDF

10. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study

Author

Praz, Fabien, Spargias, Konstantinos, Chrissoheris, Michael, Büllesfeld, Lutz, Nickenig, Georg, Deuschl, Florian, Schueler, Robert, Fam, Neil P, Moss, Robert, Makar, Moody, Boone, Robert, Edwards, Jeremy, Moschovitis, Aris, Kar, Saibal, Webb, John, Schäfer, Ulrich, Feldman, Ted, and Windecker, Stephan

Published
2017
Full Text
View/download PDF

11. Incidence and Clinical Impact of Device-Associated Thrombus and Peri-Device Leak Following Left Atrial Appendage Closure With the Amplatzer Cardiac Plug

Author

Saw, Jacqueline, Tzikas, Apostolos, Shakir, Samera, Gafoor, Sameer, Omran, Heyder, Nielsen-Kudsk, Jens Erik, Kefer, Joelle, Aminian, Adel, Berti, Sergio, Santoro, Gennaro, Nietlispach, Fabian, Moschovitis, Aris, Cruz-Gonzalez, Ignacio, Stammen, Francis, Tichelbäcker, Tobias, Freixa, Xavier, Ibrahim, Reda, Schillinger, Wolfgang, Meier, Bernhard, Sievert, Horst, and Gloekler, Steffen

Published
2017
Full Text
View/download PDF

16. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study

Author

Räber, Lorenz, Klingenberg, Roland, Heg, Dik, Kelbæk, Henning, Roffi, Marco, Tüller, David, Baumbach, Andreas, Zanchin, Thomas, Carballo, David, Ostojic, Miodrag, Stefanini, Giulio G., Rodondi, Nicolas, von Birgelen, Clemens, Moschovitis, Aris, Engstrøm, Thomas, Gencer, Baris, Auer, Reto, Meier, Bernhard, Mach, Francois, Lüscher, Thomas F., Jüni, Peter, Matter, Christian M., and Windecker, Stephan

Published
2015
Full Text
View/download PDF

17. Impact of local endothelial shear stress on neointima and plaque following stent implantation in patients with ST-elevation myocardial infarction: A subgroup-analysis of the COMFORTABLE AMI–IBIS 4 trial

Author

Bourantas, Christos V., Räber, Lorenz, Zaugg, Serge, Sakellarios, Antonis, Taniwaki, Masanori, Heg, Dik, Moschovitis, Aris, Radu, Maria, Papafaklis, Michail I., Kalatzis, Fanis, Naka, Katerina K., Fotiadis, Dimitrios I., Michalis, Lampros K., Serruys, Patrick W., Garcia Garcia, Hector M., and Windecker, Stephan

Published
2015
Full Text
View/download PDF

18. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial

Author

Pilgrim, Thomas, Heg, Dik, Roffi, Marco, Tüller, David, Muller, Olivier, Vuilliomenet, André, Cook, Stéphane, Weilenmann, Daniel, Kaiser, Christoph, Jamshidi, Peiman, Fahrni, Therese, Moschovitis, Aris, Noble, Stéphane, Eberli, Franz R, Wenaweser, Peter, Jüni, Peter, and Windecker, Stephan

Published
2014
Full Text
View/download PDF

19. Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: An optical coherence tomography study

Author

Räber, Lorenz, Zanchin, Thomas, Baumgartner, Sandro, Taniwaki, Masanori, Kalesan, Bindu, Moschovitis, Aris, Garcia-Garcia, Hector M., Justiz, Jörn, Pilgrim, Thomas, Wenaweser, Peter, Meier, Bernhard, Jüni, Peter, and Windecker, Stephan

Published
2014
Full Text
View/download PDF

21. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization

Author

Yamaji, Kyohei, Zanchin, Thomas, Zanchin, Christian, Stortecky, Stefan, Koskinas, Konstantinos C., Hunziker, Lukas, Praz, Fabien, Blöchlinger, Stefan, Moro, Christina, Moschovitis, Aris, Seiler, Christian, Valgimigli, Marco, Billinger, Michael, Pilgrim, Thomas, Heg, Dik, Windecker, Stephan, and Räber, Lorenz

Published
2018
Full Text
View/download PDF

23. Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation

Author

Gloekler, Steffen, Shakir, Samera, Doblies, Janosch, Khattab, Ahmed A., Praz, Fabien, Guerios, Ênio, Koermendy, Dezsoe, Stortecky, Stefan, Pilgrim, Thomas, Buellesfeld, Lutz, Wenaweser, Peter, Windecker, Stephan, Moschovitis, Aris, Jaguszewski, Milosz, Landmesser, Ulf, Nietlispach, Fabian, and Meier, Bernhard

Published
2015
Full Text
View/download PDF

24. Long-term safety and feasibility of three-vessel multimodality intravascular imaging in patients with ST-elevation myocardial infarction: the IBIS-4 (integrated biomarker and imaging study) substudy

Author

Taniwaki, Masanori, Radu, Maria D., Garcia-Garcia, Hector M., Heg, Dik, Kelbæk, Henning, Holmvang, Lene, Moschovitis, Aris, Noble, Stephane, Pedrazzini, Giovanni, Saunamäki, Kari, Dijkstra, Jouke, Landmesser, Ulf, Wenaweser, Peter, Meier, Bernhard, Stefanini, Giulio G., Roffi, Marco, Lüscher, Thomas F., Windecker, Stephan, and Räber, Lorenz

Published
2015
Full Text
View/download PDF

27. Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial

Author

Gragnano, Felice, primary, Zwahlen, Marcel, additional, Vranckx, Pascal, additional, Heg, Dik, additional, Schmidlin, Kurt, additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Gargiulo, Giuseppe, additional, McFadden, Eugene P., additional, Onuma, Yoshinobu, additional, Chichareon, Ply, additional, Benit, Edouard, additional, Möllmann, Helge, additional, Janssens, Luc, additional, Leonardi, Sergio, additional, Zurakowski, Aleksander, additional, Arrivi, Alessio, additional, Van Geuns, Robert Jan, additional, Huber, Kurt, additional, Slagboom, Ton, additional, Calabrò, Paolo, additional, Serruys, Patrick W., additional, Jüni, Peter, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, Abdellaoui, Mohamed, additional, Adlam, David, additional, Akin, Ibrahim, additional, Gonzalez‐Trevilla, Agustin Albarran, additional, Almeida, Manuel, additional, Neto, Pedro Alves Lemos, additional, Aminian, Adel, additional, Anderson, Richard, additional, Andreae, Rick, additional, Angioi, Michael, additional, Asano, Taku, additional, Barbato, Emanuele, additional, Barlis, Peter, additional, Barraud, Pascal, additional, Bertrand, Olivier, additional, Beygui, Farzin, additional, Bolognese, Leonardo, additional, Botelho, Roberto, additional, Bouwman, Coby, additional, Bressers, Marco, additional, Brunel, Philippe, additional, Buszman, Pawel, additional, Buysschaert, Ian, additional, da Silva, Pedro Canas, additional, Carrie, Didier, additional, Cequier, Angel, additional, Chang, Chun Chin, additional, Chowdhary, Saqib, additional, Collet, Carlos, additional, Colombo, Antonio, additional, Cotton, James, additional, Ferreira, Rui Cruz, additional, Curello, Salvatore, additional, Curzen, Nick, additional, de Bot, Judith, additional, de Vreede, Tone, additional, Karth, Georg Delle, additional, Dijksma, Lynn, additional, Dominici, Marcello, additional, Édes, István, additional, Eeckhout, Eric, additional, Eitel, Ingo, additional, Faluközy, József, additional, Fath‐Ordoubadi, Farzin, additional, Ferrario, Maurizio, additional, Fontos, Geza, additional, Diaz, Jose Francisco, additional, Quintella, Edgard Freitas, additional, Frey, Bernhard, additional, Friedrich, Guy, additional, Galasko, Gavin, additional, Galuszka, Grzegorz, additional, Ribeiro, Vasco Gama, additional, Garg, Scot, additional, Geisler, Tobias, additional, Gelev, Valeri, additional, Ghandilyan, Art, additional, Goicolea, Javier, additional, Gori, Tommaso, additional, Gragnano, Felice, additional, Guimarães, Ana, additional, Haude, Michael, additional, Heijke, Pieter, additional, Antolin, Rosa Ana Hernández, additional, Hildick‐Smith, David, additional, Hillen, Dorien, additional, Hoekman, Ina, additional, Hofma, Sjoerd, additional, Holmvang, Lene, additional, Hoole, Stephen, additional, Horváth, Iván, additional, Hugense, Annemarie, additional, Ibrahim, Karim, additional, Iñiguez, Andres, additional, Isaaz, Karl, additional, Jambrik, Zoltán, additional, Jasionowicz, Pawel, additional, Jonk, Judith, additional, Jung, Werner, additional, Katagiri, Yuki, additional, Kogame, Norihiro, additional, Koh, Tian Hai, additional, Koning, René, additional, Konteva, Mariana, additional, Kőszegi, Zsolt, additional, Krackhardt, Florian, additional, Kreuger, Yvonne, additional, Kukreja, Neville, additional, Ladan, Boudijn, additional, Lantelme, Pierre, additional, Leandro, Sergio, additional, Leibundgut, Gregor, additional, Liebetrau, Christoph, additional, Lindeboom, Wietze, additional, Miguel, Carlos Macaya, additional, Mach, François, additional, Magro, Michael, additional, Maillard, Luc, additional, Manavifar, Negar, additional, Mauri, Laura, additional, McFadden, Eugene, additional, Merkely, Bela, additional, Miyazaki, Yosuke, additional, Młodziankowski, Adam, additional, Moccetti, Tiziano, additional, Modolo, Rodrigo, additional, Möllman, Helge, additional, Morelle, Jean‐François, additional, Moschovitis, Aris, additional, Ottesen, Michael Munndt, additional, Muurling, Martin, additional, Naber, Christoph Kurt, additional, Neumann, Franz‐Josef, additional, Oldroyd, Keith, additional, Ong, Paul, additional, Palsrok, Sanne, additional, Petrov, Ivo, additional, Plante, Sylvain, additional, Prokopczuk, Janusz, additional, Rademaker‐Havinga, Tessa, additional, Raffel, Christopher, additional, Rensing, Benno, additional, Roffi, Marco, additional, Royaards, Kees‐Jan, additional, Sabate, Manel, additional, Schächinger, Volker, additional, Seidler, Tim, additional, Peñaranda, Antonio Serra, additional, Serruys, Patrick, additional, Sikarulidze, Lali, additional, Soliman, Osama I, additional, Sousa, Amanda, additional, Spitzer, Ernest, additional, Stables, Rod, additional, Steg, Gabriel, additional, Steinwender, Clemens, additional, Subkovas, Eduardas, additional, Suryapranata, Harry, additional, Takahashi, Kuniaki, additional, Talwar, Suneel, additional, Teiger, Emmanuel, additional, Weele, Addy Ter, additional, Teurlings, Eva, additional, Thury, Attila, additional, Tijssen, Jan, additional, Tonev, Gincho, additional, Trendafilova‐Lazarova, Diana, additional, Tumscitz, Carlo, additional, Umans, Victor, additional, Ungi, Imre, additional, Valkov, Veselin, additional, van der Harst, Pim, additional, van Geuns, Robert Jan, additional, van Meijeren, Cokky, additional, Vassilev, Dobrin, additional, Velchev, Vasil, additional, Velthuizen, Esther, additional, Verheugt, Freek, additional, Vlcek, Natalia, additional, Dahl, Jürgen Vom, additional, Vrolix, Mathias, additional, Walsh, Simon, additional, Werner, Nikos, additional, Witsenburg, Maarten, additional, Zaman, Azfar, additional, Żmudka, Krzysztof, additional, Zrenner, Bernhard, additional, and Zweiker, Robert, additional

Published
2022
Full Text
View/download PDF

31. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk

Author

Valgimigli, Marco, primary, Frigoli, Enrico, additional, Heg, Dik, additional, Tijssen, Jan, additional, Jüni, Peter, additional, Vranckx, Pascal, additional, Ozaki, Yukio, additional, Morice, Marie-Claude, additional, Chevalier, Bernard, additional, Onuma, Yoshinobu, additional, Windecker, Stephan, additional, Tonino, Pim A.L., additional, Roffi, Marco, additional, Lesiak, Maciej, additional, Mahfoud, Felix, additional, Bartunek, Jozef, additional, Hildick-Smith, David, additional, Colombo, Antonio, additional, Stanković, Goran, additional, Iñiguez, Andrés, additional, Schultz, Carl, additional, Kornowski, Ran, additional, Ong, Paul J.L., additional, Alasnag, Mirvat, additional, Rodriguez, Alfredo E., additional, Moschovitis, Aris, additional, Laanmets, Peep, additional, Donahue, Michael, additional, Leonardi, Sergio, additional, and Smits, Pieter C., additional

Published
2021
Full Text
View/download PDF

35. Impact of Echocardiographic Guidance on Safety and Efficacy of Left Atrial Appendage Closure: An Observational Study

Author

Galea, Roberto, Räber, Lorenz, Fuerholz, Monika, Häner, Jonas D, Siontis, George C M, Brugger, Nicolas, Moschovitis, Aris, Heg, Dik, Fischer, Urs, Meier, Bernhard, Windecker, Stephan, and Valgimigli, Marco

Subjects
610 Medicine & health
Abstract

OBJECTIVES The aim of this study was to evaluate the impact of echocardiographic guidance on the safety and efficacy of left atrial appendage closure (LAAC). BACKGROUND Expert consensus documents recommend intraprocedural imaging by means of either transesophageal echocardiography or intracardiac echocardiography to guide LAAC. However, no evidence exists that intraprocedural echocardiographic guidance in addition to fluoroscopy improves the safety and efficacy of LAAC. METHODS Consecutive LAAC procedures performed at a high-volume center between January 2009 and October 2020 were stratified on the basis of intraprocedural imaging modalities, including fluoroscopic guidance (FG) only or intraprocedural echocardiographic guidance (EG) in addition to fluoroscopy. The primary safety endpoint was the composite of procedure-related complications occurring within 7 days after the procedure. Technical success at 7 days and at follow-up were secondary endpoints. RESULTS Among 811 LAAC procedures, 549 (67.7%) and 262 (32.3%) were assigned to the FG and EG groups, respectively. After adjusting for confounders, EG remained associated with a lower rate of the primary safety endpoint (3.4% vs 9.1%; P = 0.004; adjusted odds ratio [OR]: 0.31; 95% CI: 0.11-0.90; P = 0.030). Technical success trended higher at 7 days (92.1% vs 87.2%; P = 0.065; adjusted OR: 1.68; 95% CI: 0.95-3.01; P = 0.079) and was significantly improved with EG compared with FG (87.6% vs 79.9%; P = 0.018; OR: 4.06; 95% CI: 1.60-10.27; P = 0.003) after a median follow-up period of 4.9 months (interquartile range: 3.4 months-6.2 months). CONCLUSIONS In a large cohort of consecutive LAACs, the use of intraprocedural echocardiography to guide intervention in addition to standard fluoroscopy was associated with lower risks for procedural complications and higher mid-term technical success rates.

Published
2021
Full Text
View/download PDF

36. Long-term safety and feasibility of three-vessel multimodality intravascular imaging in patients with ST-elevation myocardial infarction: the IBIS-4 (integrated biomarker and imaging study) substudy

Author

Taniwaki, Masanori, Radu, Maria, Garcia-Garcia, Hector, Heg, Dik, Kelbæk, Henning, Holmvang, Lene, Moschovitis, Aris, Noble, Stephane, Pedrazzini, Giovanni, Saunamäki, Kari, Dijkstra, Jouke, Landmesser, Ulf, Wenaweser, Peter, Meier, Bernhard, Stefanini, Giulio, Roffi, Marco, Lüscher, Thomas, Windecker, Stephan, Räber, Lorenz, Taniwaki, Masanori, Radu, Maria, Garcia-Garcia, Hector, Heg, Dik, Kelbæk, Henning, Holmvang, Lene, Moschovitis, Aris, Noble, Stephane, Pedrazzini, Giovanni, Saunamäki, Kari, Dijkstra, Jouke, Landmesser, Ulf, Wenaweser, Peter, Meier, Bernhard, Stefanini, Giulio, Roffi, Marco, Lüscher, Thomas, Windecker, Stephan, and Räber, Lorenz

Abstract

We assessed the feasibility and the procedural and long-term safety of intracoronary (i.c) imaging for documentary purposes with optical coherence tomography (OCT) and intravascular ultrasound (IVUS) in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary PCI in the setting of IBIS-4 study. IBIS4 (NCT00962416) is a prospective cohort study conducted at five European centers including 103 STEMI patients who underwent serial three-vessel coronary imaging during primary PCI and at 13months. The feasibility parameter was successful imaging, defined as the number of pullbacks suitable for analysis. Safety parameters included the frequency of peri-procedural complications, and major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI) and any clinically-indicated revascularization at 2years. Clinical outcomes were compared with the results from a cohort of 485 STEMI patients undergoing primary PCI without additional imaging. Imaging of the infarct-related artery at baseline (and follow-up) was successful in 92.2% (96.6%) of patients using OCT and in 93.2% (95.5%) using IVUS. Imaging of the non-infarct-related vessels was successful in 88.7% (95.6%) using OCT and in 90.5% (93.3%) using IVUS. Periprocedural complications occurred <2.0% of OCT and none during IVUS. There were no differences throughout 2years between the imaging and control group in terms of MACE (16.7 vs. 13.3%, adjusted HR1.40, 95% CI 0.77-2.52, p=0.27). Multi-modality three-vessel i.c. imaging in STEMI patients undergoing primary PCI is consistent a high degree of success and can be performed safely without impact on cardiovascular events at long-term follow-up.

Published
2021

37. Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation

Author

Gloekler, Steffen, Shakir, Samera, Doblies, Janosch, Khattab, Ahmed, Praz, Fabien, Guerios, Ênio, Koermendy, Dezsoe, Stortecky, Stefan, Pilgrim, Thomas, Buellesfeld, Lutz, Wenaweser, Peter, Windecker, Stephan, Moschovitis, Aris, Jaguszewski, Milosz, Landmesser, Ulf, Nietlispach, Fabian, Meier, Bernhard, Gloekler, Steffen, Shakir, Samera, Doblies, Janosch, Khattab, Ahmed, Praz, Fabien, Guerios, Ênio, Koermendy, Dezsoe, Stortecky, Stefan, Pilgrim, Thomas, Buellesfeld, Lutz, Wenaweser, Peter, Windecker, Stephan, Moschovitis, Aris, Jaguszewski, Milosz, Landmesser, Ulf, Nietlispach, Fabian, and Meier, Bernhard

Abstract

Background: Transcatheter left atrial appendage (LAA) occlusion has been proven to be an effective treatment for stroke prophylaxis in patients with atrial fibrillation. For this purpose, the Amplatzer cardiac plug (ACP) was introduced. Its second generation, the Amulet, was developed for easier delivery, better coverage, and reduction of complications. Aim: To investigate the safety and efficacy of first generation versus second generation Amplatzer occluders for LAA occlusion. Methods: Retrospective analysis of prospectively collected data from the LAA occlusion registries of the Bern and Zurich university hospitals. Comparison of the last consecutive 50 ACP cases versus the first consecutive 50 Amulet cases in patients with non-valvular atrial fibrillation. For safety, a periprocedural combined endpoint, which is composed of death, stroke, cardiac tamponade, and bailout by surgery was predefined. For efficacy, the endpoint was procedural success. Results: There were no differences between the two groups in baseline characteristics. The percentage of associated interventions during LAA occlusion was high in (78% with ACP vs. 70% with Amulet p=ns). Procedural success was similar in both groups (98 vs. 94%, p=0.61). The combined safety endpoint for severe adverse events was reached by a similar rate of patients in both groups (6 vs. 8%, p=0.7). Overall complication rate was insignificantly higher in the ACP group, which was mainly driven by clinically irrelevant pericardial effusions (24 vs. 14%, p=0.31). Death, stroke, or tamponade were similar between the groups (0 vs. 2%, 0 vs. 0%, or 6 vs. 6%, p=ns). Conclusion: Transcatheter LAA occlusion for stroke prophylaxis in patients with atrial fibrillation can be performed with similarly high success rates with first and second generations of Amplatzer occluders. According to this early experience, the Amulet has failed to improve results of LAA occlusion. The risk for major procedural adverse events is acceptable but h

Published
2021

39. Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial: A Post Hoc Analysis of the Global Leaders Trial

Author

Takahashi, Kuniaki, Chichareon, Ply, Modolo, Rodrigo, Kogame, Norihiro, Chang, Chun Chin, Tomaniak, Mariusz, Moschovitis, Aris, Curzen, Nick, Haude, Michael, Jung, Werner, Holmvang, Lene, Garg, Scot, Tijssen, Jan G P, Wykrzykowska, Joanna J, de Winter, Robbert J, Hamm, Christian, Steg, Philippe Gabriel, Stoll, Hans-Peter, Onuma, Yoshinobu, Valgimigli, Marco, Vranckx, Pascal, Windecker, Stephan, Serruys, Patrick W, Graduate School, ACS - Atherosclerosis & ischemic syndromes, Cardiology, ACS - Heart failure & arrhythmias, and ACS - Microcirculation

Subjects
Stable angina, ACS/NSTE-ACS, Adjunctive pharmacotherapy, Drug-eluting stent
Abstract

AIMS: The aim of this study was to evaluate the impact of a novel antiplatelet regimen in patients with increasing total stent length (TSL). METHODS AND RESULTS: This is a post hoc analysis of the GLOBAL LEADERS trial, a prospective, multicentre, open-label, randomised trial, investigating the impact of the experimental strategy (one-month dual antiplatelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) versus the reference regimen (12-month DAPT followed by 12-month aspirin monotherapy) in patients with a Biolimus A9-eluting stent (BES). The primary endpoint was the composite of all-cause death and new Q-wave myocardial infarction (MI), and the secondary endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at two years. To investigate the association between total stent length and outcomes, groups were compared in quartiles according to TSL; the fourth quartile group was at significantly higher ischaemic risk at two years. In that stratum (TSL ≥46 mm), the experimental strategy significantly reduced the risk of the primary endpoint (hazard ratio [HR] 0.67, 95% confidence interval [CI]: 0.49-0.90; pinteraction=0.043), while demonstrating a similar risk of BARC type 3 or 5 bleeding (HR 0.99, 95% CI: 0.66-1.49; pinteraction=0.975). CONCLUSIONS: Ticagrelor monotherapy could potentially balance ischaemic and bleeding risks, thereby achieving a net clinical benefit in patients with a TSL ≥46 mm with a BES.

Published
2020

40. Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting:A post hoc analysis of the GLOBAL LEADERS trial

Author

Takahashi, Kuniaki, Chichareon, Ply, Modolo, Rodrigo, Kogame, Norihiro, Chang, Chun Chin, Tomaniak, Mariusz, Moschovitis, Aris, Curzen, Nick, Haude, Michael, Jung, Werner, Holmvang, Lene, Garg, Scot, Tijssen, Jan G.P., Wykrzykowska, Joanna J., De Winter, Robbert J., Hamm, Christian, Steg, Philippe Gabriel, Stoll, Hans Peter, Onuma, Yoshinobu, Valgimigli, Marco, Vranckx1, Pascal, Windecker, Stephan, Serruys, Patrick W., Takahashi, Kuniaki, Chichareon, Ply, Modolo, Rodrigo, Kogame, Norihiro, Chang, Chun Chin, Tomaniak, Mariusz, Moschovitis, Aris, Curzen, Nick, Haude, Michael, Jung, Werner, Holmvang, Lene, Garg, Scot, Tijssen, Jan G.P., Wykrzykowska, Joanna J., De Winter, Robbert J., Hamm, Christian, Steg, Philippe Gabriel, Stoll, Hans Peter, Onuma, Yoshinobu, Valgimigli, Marco, Vranckx1, Pascal, Windecker, Stephan, and Serruys, Patrick W.

Abstract

Aims: The aim of this study was to evaluate the impact of a novel antiplatelet regimen in patients with increasing total stent length (TSL). Methods and results: This is a post hoc analysis of the GLOBAL LEADERS trial, a prospective, multicentre, open-label, randomised trial, investigating the impact of the experimental strategy (one-month dual antiplatelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) versus the reference regimen (12-month DAPT followed by 12-month aspirin monotherapy) in patients with a Biolimus A9-eluting stent (BES). The primary endpoint was the composite of all-cause death and new Q-wave myocardial infarction (MI), and the secondary endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at two years. To investigate the association between total stent length and outcomes, groups were compared in quartiles according to TSL; the fourth quartile group was at significantly higher ischaemic risk at two years. In that stratum (TSL ≥46 mm), the experimental strategy significantly reduced the risk of the primary endpoint (hazard ratio [HR] 0.67, 95% confidence interval [CI]: 0.49-0.90; pinteraction=0.043), while demonstrating a similar risk of BARC type 3 or 5 bleeding (HR 0.99, 95% CI: 0.66-1.49; pinteraction=0.975). Conclusions: Ticagrelor monotherapy could potentially balance ischaemic and bleeding risks, thereby achieving a net clinical benefit in patients with a TSL ≥46 mm with a BES.

Published
2020

41. Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial

Author

Takahashi, Kuniaki, Chichareon, Ply, Modolo, Rodrigo, Kogame, Norihiro, Chang, Chun Chin, Tomaniak, Mariusz, Moschovitis, Aris, Curzen, Nick, Haude, Michael, Jung, Werner, Holmvang, Lene, Garg, Scot, Tijssen, Jan G P, Wykrzykowska, Joanna J, de Winter, Robbert J, Hamm, Christian, Steg, Philippe Gabriel, Stoll, Hans-Peter, Onuma, Yoshinobu, Valgimigli, Marco, Vranckx, Pascal, Windecker, Stephan, Serruys, Patrick W, Takahashi, Kuniaki, Chichareon, Ply, Modolo, Rodrigo, Kogame, Norihiro, Chang, Chun Chin, Tomaniak, Mariusz, Moschovitis, Aris, Curzen, Nick, Haude, Michael, Jung, Werner, Holmvang, Lene, Garg, Scot, Tijssen, Jan G P, Wykrzykowska, Joanna J, de Winter, Robbert J, Hamm, Christian, Steg, Philippe Gabriel, Stoll, Hans-Peter, Onuma, Yoshinobu, Valgimigli, Marco, Vranckx, Pascal, Windecker, Stephan, and Serruys, Patrick W

Abstract

Aims: The aim of this study was to evaluate the impact of a novel antiplatelet regimen in patients with increasing total stent length (TSL). Methods and results: This is a post hoc analysis of the GLOBAL LEADERS trial, a prospective, multicentre, open-label, randomised trial, investigating the impact of the experimental strategy (one-month dual antiplatelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) versus the reference regimen (12-month DAPT followed by 12-month aspirin monotherapy) in patients with a Biolimus A9-eluting stent (BES). The primary endpoint was the composite of all-cause death and new Q-wave myocardial infarction (MI), and the secondary endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at two years. To investigate the association between total stent length and outcomes, groups were compared in quartiles according to TSL; the fourth quartile group was at significantly higher ischaemic risk at two years. In that stratum (TSL ≥46 mm), the experimental strategy significantly reduced the risk of the primary endpoint (hazard ratio [HR] 0.67, 95% confidence interval [CI]: 0.49-0.90; pinteraction=0.043), while demonstrating a similar risk of BARC type 3 or 5 bleeding (HR 0.99, 95% CI: 0.66-1.49; pinteraction=0.975). Conclusions: Ticagrelor monotherapy could potentially balance ischaemic and bleeding risks, thereby achieving a net clinical benefit in patients with a TSL ≥46 mm with a BES.

Published
2020

43. Effect of Biolimus-Eluting Stents With Biodegradable Polymer vs Bare-Metal Stents on Cardiovascular Events Among Patients With Acute Myocardial Infarction: The COMFORTABLE AMI Randomized Trial

Author

Räber, Lorenz, Kelbæk, Henning, Ostoijc, Miodrag, Baumbach, Andreas, Heg, Dik, Tüller, David, von Birgelen, Clemens, Roffi, Marco, Moschovitis, Aris, Khattab, Ahmed A., Wenaweser, Peter, Bonvini, Robert, Pedrazzini, Giovanni, Kornowski, Ran, Weber, Klaus, Trelle, Sven, Lüscher, Thomas F., Taniwaki, Masanori, Matter, Christian M., Meier, Bernhard, Jüni, Peter, and Windecker, Stephan

Published
2012
Full Text
View/download PDF

45. Cell-based therapy for myocardial repair in patients with acute myocardial infarction: Rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI)

Author

Sürder, Daniel, Schwitter, Jürg, Moccetti, Tiziano, Astori, Giuseppe, Rufibach, Kaspar, Plein, Sven, Cicero, Viviana Lo, Soncin, Sabrina, Windecker, Stephan, Moschovitis, Aris, Wahl, Andreas, Erne, Paul, Jamshidi, Peiman, Auf der Maur, Christoph, Manka, Robert, Soldati, Gianni, Bühler, Ines, Wyss, Christophe, Landmesser, Ulf, Lüscher, Thomas F., and Corti, Roberto

Published
2010

47. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study

Author

Frigoli, Enrico, Smits, Pieter, Vranckx, Pascal, Ozaki, Yokio, Tijssen, Jan, Juni, Peter, Morice, Marie-Claude, Onuma, Yoshinobu, Windecker, Stephan, Frenk, Andre, Spaulding, Christian, Chevalier, Bernard, Barbato, Emanuele, Tonino, Pim, Hildick-Smith, David, Roffi, Marco, Kornowski, Ran, Schultz, Carl, Lesiak, Maciej, Iniguez, Andres, Colombo, Antonio, Alasnag, Mirvat, Mullasari, Ajit, James, Stefan K, Stankovic, Goran, Ong, Paul J. L., Rodriguez, Alfredo E., Mahfoud, Felix, Bartunek, Jozef, Moschovitis, Aris, Laanmets, Peep, Leonardi, Sergio, Heg, Dik, Sunnaker, Mikael, Valgimigli, Marco, Frigoli, Enrico, Smits, Pieter, Vranckx, Pascal, Ozaki, Yokio, Tijssen, Jan, Juni, Peter, Morice, Marie-Claude, Onuma, Yoshinobu, Windecker, Stephan, Frenk, Andre, Spaulding, Christian, Chevalier, Bernard, Barbato, Emanuele, Tonino, Pim, Hildick-Smith, David, Roffi, Marco, Kornowski, Ran, Schultz, Carl, Lesiak, Maciej, Iniguez, Andres, Colombo, Antonio, Alasnag, Mirvat, Mullasari, Ajit, James, Stefan K, Stankovic, Goran, Ong, Paul J. L., Rodriguez, Alfredo E., Mahfoud, Felix, Bartunek, Jozef, Moschovitis, Aris, Laanmets, Peep, Leonardi, Sergio, Heg, Dik, Sunnaker, Mikael, and Valgimigli, Marco

Abstract

Background The optimal duration of antiplatelet therapy in high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable polymer-coated stents remains unclear. Design MASTER DAPT (clinicaltrial.gov NCT03023020) is an investigator-initiated, open-label, multicenter, randomized controlled trial comparing an abbreviated versus a standard duration of antiplatelet therapy after bioresorbable polymer-coated Ultimaster (TANSEI) sirolimus-eluting stent implantation in approximately 4,300 HBR patients recruited from >= 100 interventional cardiology centers globally. After a mandatory 30-day dual-antiplatelet therapy (DAPT) run-in phase, patients are randomized to (a) a single antiplatelet regimen until study completion or up to 5 months in patients with clinically indicated oral anticoagulation (experimental 1-month DAPT group) or (b) continue DAPT for at least 5 months in patients without or 2 in patients with concomitant indication to oral anticoagulation, followed by a single antiplatelet regimen (standard antipkitelet regimen). With a final sample size of 4,300 patients, this study is powered to assess the noninferiority of the abbreviated antiplatelet regimen with respect to the net adverse clinical and major adverse cardiac and cerebral events composite end points and if satisfied for the superiority of abbreviated as compared to standard antiplatelet therapy duration in terms of major or clinically relevant nonmajor bleeding. Study end points will be adjudicated by a blinded Clinical Events Committee. Conclusions The MASTER DAPT study is the first randomized controlled trial aiming at ascertaining the optimal duration of antiplatelet therapy in HBR patients treated with sirolimus-eluting bioresorbable polymer-coated stent implantation.

Published
2019
Full Text
View/download PDF

48. Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial:randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction

Author

Räber, Lorenz, Yamaji, Kyohei, Kelbæk, Henning, Engstrøm, Thomas, Baumbach, Andreas, Roffi, Marco, Von Birgelen, Clemens, Taniwaki, Masanori, Moschovitis, Aris, Zaugg, Serge, Ostojic, Miodrag, Pedrazzini, Giovanni, Karagiannis-Voules, Dimitrios-Alexios, Lüscher, Thomas F, Kornowski, Ran, Tüller, David, Vukcevic, Vladan, Heg, Dik, Windecker, Stephan, Räber, Lorenz, Yamaji, Kyohei, Kelbæk, Henning, Engstrøm, Thomas, Baumbach, Andreas, Roffi, Marco, Von Birgelen, Clemens, Taniwaki, Masanori, Moschovitis, Aris, Zaugg, Serge, Ostojic, Miodrag, Pedrazzini, Giovanni, Karagiannis-Voules, Dimitrios-Alexios, Lüscher, Thomas F, Kornowski, Ran, Tüller, David, Vukcevic, Vladan, Heg, Dik, and Windecker, Stephan

Published
2019

50. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Author

Vranckx, Pascal, Valgimigli, Marco, Jüni, Peter, Hamm, Christian, Steg, Philippe Gabriel, Heg, Dik, Van Es, Gerrit Anne, McFadden, Eugene P, Onuma, Yoshinobu, Van Meijeren, Cokky, Chichareon, Ply, Benit, Edouard, Möllmann, Helge, Janssens, Luc, Ferrario, Maurizio, Moschovitis, Aris, Zurakowski, Aleksander, Dominici, Marcello, Van Geuns, Robert Jan, Huber, Kurt, Slagboom, Ton, Serruys, Patrick W, Windecker, Stephan, and Investigators, GLOBAL LEADERS

Subjects
610 Medicine & health, 360 Social problems & social services
Abstract

BACKGROUND We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens. METHODS GLOBAL LEADERS was a randomised, open-label superiority trial at 130 sites in 18 countries. Patients undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or acute coronary syndromes were randomly assigned (1:1) to 75-100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy, or standard dual antiplatelet therapy with 75-100 mg aspirin daily plus either 75 mg clopidogrel daily (for patients with stable coronary artery disease) or 90 mg ticagrelor twice daily (for patients with acute coronary syndromes) for 12 months, followed by aspirin monotherapy for 12 months. Randomisation was concealed, stratified by centre and clinical presentation (stable coronary artery disease vs acute coronary syndrome), and blocked, with randomly varied block sizes of two and four. The primary endpoint at 2 years was a composite of all-cause mortality or non-fatal centrally adjudicated new Q-wave myocardial infarction as assessed by a core lab in a blinded manner. The key secondary safety endpoint was site-reported bleeding assessed according to the Bleeding Academic Research Consortium criteria (grade 3 or 5). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01813435, and is closed to new participants, with follow-up completed. FINDINGS Between July 1, 2013, and Nov 9, 2015, 15 968 participants were randomly assigned, 7980 to the experimental group and 7988 to the control group. At 2 years, 304 (3·81%) participants in the experimental group had died or had a non-fatal centrally adjudicated new Q-wave myocardial infarction, compared with 349 (4·37%) participants in the control group (rate ratio 0·87 [95% CI 0·75-1·01]; p=0·073]). There was no evidence for a difference in treatment effects for the primary endpoint across prespecified subgroups of acute coronary syndromes and stable coronary artery disease (p=0·93). Grade 3 or 5 bleeding occurred in 163 participants in the experimental group and 169 in the control group (2·04% vs 2·12%; rate ratio 0·97 [95% CI 0·78-1·20]; p=0·77). INTERPRETATION Ticagrelor in combination with aspirin for 1 month followed by ticagrelor alone for 23 months was not superior to 12 months of standard dual antiplatelet therapy followed by 12 months of aspirin alone in the prevention of all-cause mortality or new Q-wave myocardial infarction 2 years after percutaneous coronary intervention. FUNDING AstraZeneca, Biosensors, and The Medicines Company.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results